The NOTCH1 and miR-34a signaling network is affected by TP53 alterations in CLL

被引:1
作者
Ehrmann, Alena Sophie [1 ,2 ]
Zadro, Alex [1 ]
Tausch, Eugen [1 ,3 ]
Schneider, Christof [1 ,3 ]
Stilgenbauer, Stephan [1 ,3 ]
Mertens, Daniel [1 ,2 ]
机构
[1] Univ Ulm, Dept Internal Med 3, Div CLL, Ulm, Germany
[2] German Canc Res Ctr, Mech Leukemogenesis B061, Heidelberg, Germany
[3] Univ Hosp Ulm, Comprehens Canc Ctr Ulm CCCU, Ulm, Germany
关键词
CLL; NOTCH1; p53; miR-34a; signaling network; CHRONIC LYMPHOCYTIC-LEUKEMIA; TUMOR-SUPPRESSOR; CELL-PROLIFERATION; POSITIVE FEEDBACK; GENE-EXPRESSION; MED12; MUTATIONS; P53; TARGET; ACTIVATION; APOPTOSIS; CROSSTALK;
D O I
10.1080/10428194.2024.2392839
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In chronic lymphocytic leukemia (CLL), TP53 mutations or deletions on chromosome 17p lead to adverse prognosis and reduced levels of miR-34a, which targets NOTCH1. Also, hyperactivated NOTCH1 signaling is crucial for CLL progression. Here we explored the interaction between p53, miR-34a, and NOTCH1 in CLL. We investigated the effect of p53 and miR-34a on NOTCH1 signaling and expression in CLL cells with altered TP53. Our results indicate that miR-34a reduces NOTCH1 3' UTR activity but might not be a mediator between p53 signaling and NOTCH1. p53 activation increases miR-34a expression and NOTCH1 protein levels, correlating with decreased NOTCH1 and miR-34a levels in primary CLL cells with TP53 alterations. Some samples with high NOTCH1 levels presented increased BCL-2, suggesting an anti-apoptotic mechanism of a potentially direct p53-NOTCH1 relation in CLL. This study deepens the understanding of the p53-miR-34a-NOTCH1 signaling network, providing insights that could guide future therapeutic strategies for CLL.
引用
收藏
页码:1941 / 1953
页数:13
相关论文
共 71 条
[51]   RNA-binding proteins and exoribonucleases modulating miRNA in cancer: the enemy within [J].
Seo, Yoona ;
Rhim, Jiho ;
Kim, Jong Heon .
EXPERIMENTAL AND MOLECULAR MEDICINE, 2024, 56 (05) :1080-1106
[52]   Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial [J].
Stilgenbauer, Stephan ;
Schnaiter, Andrea ;
Paschka, Peter ;
Zenz, Thorsten ;
Rossi, Marianna ;
Doehner, Konstanze ;
Buehler, Andreas ;
Boettcher, Sebastian ;
Ritgen, Matthias ;
Kneba, Michael ;
Winkler, Dirk ;
Tausch, Eugen ;
Hoth, Patrick ;
Edelmann, Jennifer ;
Mertens, Daniel ;
Bullinger, Lars ;
Bergmann, Manuela ;
Kless, Sabrina ;
Mack, Silja ;
Jaeger, Ulrich ;
Patten, Nancy ;
Wu, Lin ;
Wenger, Michael K. ;
Fingerle-Rowson, Guenter ;
Lichter, Peter ;
Cazzola, Mario ;
Wendtner, Clemens M. ;
Fink, Anna M. ;
Fischer, Kirsten ;
Busch, Raymonde ;
Hallek, Michael ;
Doehner, Hartmut .
BLOOD, 2014, 123 (21) :3247-3254
[53]   Differential regulation of microRNAs by p53 revealed by massively parallel Sequencing -: miR-34a is a p53 target that induces apoptosis and G1-arrest [J].
Tarasov, Valery ;
Jung, Peter ;
Verdoodt, Berlinda ;
Lodygin, Dmitri ;
Epanchintsev, Alexey ;
Menssen, Antje ;
Meister, Gunter ;
Hermeking, Heiko .
CELL CYCLE, 2007, 6 (13) :1586-1593
[54]   Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1 [J].
Tausch, Eugen ;
Beck, Philipp ;
Schlenk, Richard F. ;
Jebaraj, Billy M. C. ;
Dolnik, Anna ;
Yosifov, Deyan Y. ;
Hillmen, Peter ;
Offner, Fritz ;
Janssens, Ann ;
Babu, K. Govind ;
Grosicki, Sebastian ;
Mayer, Jiri ;
Panagiotidis, Panagiotis ;
McKeown, Astrid ;
Gupta, Ira V. ;
Skorupa, Alexandra ;
Pallaud, Celine ;
Bullinger, Lars ;
Mertens, Daniel ;
Doehner, Hartmut ;
Stilgenbauer, Stephan .
HAEMATOLOGICA, 2020, 105 (10) :2440-2447
[55]   The multilayered complexity of ceRNA crosstalk and competition [J].
Tay, Yvonne ;
Rinn, John ;
Pandolfi, Pier Paolo .
NATURE, 2014, 505 (7483) :344-352
[56]   MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia [J].
Vargova, Karin ;
Curik, Nikola ;
Burda, Pavel ;
Basova, Petra ;
Kulvait, Vojtech ;
Pospisil, Vit ;
Savvulidi, Filipp ;
Kokavec, Juraj ;
Necas, Emanuel ;
Berkova, Adela ;
Obrtlikova, Petra ;
Karban, Josef ;
Mraz, Marek ;
Pospisilova, Sarka ;
Mayer, Jiri ;
Trneny, Marek ;
Zavadil, Jiri ;
Stopka, Tomas .
BLOOD, 2011, 117 (14) :3816-3825
[57]   In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 [J].
Vassilev, LT ;
Vu, BT ;
Graves, B ;
Carvajal, D ;
Podlaski, F ;
Filipovic, Z ;
Kong, N ;
Kammlott, U ;
Lukacs, C ;
Klein, C ;
Fotouhi, N ;
Liu, EA .
SCIENCE, 2004, 303 (5659) :844-848
[58]   Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia [J].
Wang, Xi ;
Li, Jinge ;
Dong, Ke ;
Lin, Fang ;
Long, Min ;
Ouyang, Yongri ;
Wei, Junxia ;
Chen, Xi ;
Weng, Yuanyuan ;
He, Ting ;
Zhang, Huizhong .
CELLULAR SIGNALLING, 2015, 27 (03) :443-452
[59]   MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells [J].
Welch, C. ;
Chen, Y. ;
Stallings, R. L. .
ONCOGENE, 2007, 26 (34) :5017-5022
[60]   p53 in the DNA-Damage-Repair Process [J].
Williams, Ashley B. ;
Schumacher, Bjoern .
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2016, 6 (05)